Dup15q Syndrome Drug Market is Projected to Grow Significantly During the Study Period (2019–2032) | DelveInsight [Yahoo! Finance]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Yahoo! Finance
New York, USA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Dup15q Syndrome Drug Market is Projected to Grow Significantly During the Study Period (2019–2032) | DelveInsight An increase in the prevalence, identification of new biomarkers, increased awareness, and expected launch of emerging therapies will boost the dup15q syndrome market in the forecasted period (2023–2032). DelveInsight's Dup15q Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, dup15q syndrome emerging drugs, market share of individual therapies, and current and forecasted dup15q syndrome market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Dup15q Syndrome Market Report According to DelveInsight's analysis, the market size for dup15q syndrome reached USD 18 million in 2021 across the 7MM and is expected to grow with a significant CAGR by 2032. Delve
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewswire
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswire
OVID
Earnings
- 5/14/24 - Beat
OVID
Sec Filings
- 5/14/24 - Form S-8
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- OVID's page on the SEC website